Overview

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

Status:
Not yet recruiting
Trial end date:
2024-06-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of parsclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),
Phase:
Phase 3
Details
Lead Sponsor:
Incyte Corporation